Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

Now Viewing

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

Video content above is prompted by the following:

What considerations should guide the sequencing of bispecific therapies in first-line vs later-line settings?